AMPK通过乙酰辅酶A稳态调控BRD4招募影响急性髓系白血病表观基因组
该研究探讨AMPK如何通过乙酰辅酶A(acetyl-CoA)稳态影响MLL重排急性髓系白血病(AML)的表观基因组。研究发现AMPK缺失降低acetyl-CoA和组蛋白乙酰化,使BET蛋白从染色质上脱离;在 mice 和患者来源异种移植AML模型中,AMPK抑制剂与BET抑制剂联用协同抑制AML。
要点
- AMPK缺失降低acetyl-CoA和组蛋白乙酰化,使BET蛋白从白血病起始细胞染色质上脱离。
- 在 mice 和患者来源异种移植AML模型中,AMPK与BET抑制剂联用协同抑制AML。
- 研究提示靶向AMPK和BET可能成为AML治疗策略。
核心结论
- AMPK通过连接acetyl-CoA稳态与BET蛋白染色质招募来维持MLL重排AML的表观基因组,联合靶向AMPK和BET可协同抑制AML。
研究设计与样本
- 研究使用MLL重排AML模型,包括 mice 和患者来源异种移植AML模型,进行AMPK缺失及AMPK/BET抑制剂联合处理实验。
主要发现
- AMPK缺失降低acetyl-CoA和组蛋白乙酰化,使BET蛋白从白血病起始细胞染色质上脱离。
- 在 mice 和患者来源异种移植AML模型中,AMPK抑制剂与BET抑制剂联用协同抑制AML。
临床怎么用
- 研究结果为靶向AMPK和BET联合治疗AML提供了治疗依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Altered metabolism fuels 2 hallmark properties of cancer cells: unlimited proliferation and differentiation blockade. Adenosine monophosphate-activated protein kinase (AMPK) is a master regulator of bioenergetics crucial for glucose metabolism in acute myeloid leukemia (AML), and its inhibition delays leukemogenesis, but whether the metabolic function of AMPK alters the AML epigenome remains unknown. Here, we demonstrate that AMPK maintains the epigenome of MLL-rearranged AML by linking acetyl-coenzyme A (CoA) homeostasis to Bromodomain and Extra-Terminal domain (BET) protein recruitment to chromatin. AMPK deletion reduced acetyl-CoA and histone acetylation, displacing BET proteins from chromatin in leukemia-initiating cells. In both mouse and patient-derived xenograft AML models, treating with AMPK and BET inhibitors synergistically suppressed AML. Our results provide a therapeutic rationale to target AMPK and BET for AML therapy.
引用
- Jiang Y, Hu T, Wang T, et al. AMP-activated protein kinase links acetyl-CoA homeostasis to BRD4 recruitment in acute myeloid leukemia. Blood. 2019. PMID: 31697807. doi:10.1182/blood.2019001076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。